Wm. Kevin Kelly, DO, Elected as Co-Chair of NCI Steering Committee

20
Mar

Headshot of Kevin Kelly, DOWm. Kevin Kelly, DO, leader of the Prostate Cancer Program and associate director of Clinical Research at the Sidney Kimmel Cancer Center at Jefferson Health (SKCC), has been elected to serve as medical oncology co-chair on the National Cancer Institute (NCI) Genitourinary Cancers Steering Committee (GUSC).

The GUSC addresses the design, prioritization, and evaluation of concepts for phase II and III clinical trials in genitourinary cancers. The committee’s goal is to promote the best clinical and translational research that will have the biggest impact on patient care.

“It is a privilege to serve as a co-leader on the NCI Genitourinary Task Force, which has the responsibility in guiding the next generation of clinical trials to improve the lives and suffering of patients with genitourinary tumors,” Kelly said.

Kelly, who is also professor of Medical Oncology and Urology and director of the Division of Solid Tumor Oncology, is a leader in the field of genitourinary oncology and an internationally respected clinical researcher. He has expertise in drug and biomarker development in prostate and bladder cancers and has been instrumental in defining the use of many novel therapies and biomarkers in patients with all stages of prostate cancer.

Since joining SKCC in 2010, Kelly has developed disease-specific research and domains in each major area of solid tumor oncology and has increased the number of investigator-initiated trials. His leadership helped establish SKCC as one of the top cancer centers nationwide for accrual of patients to clinical trials, and the Prostate Cancer Program was recently ranked Outstanding by the NCI.

Kelly has received funding from the Prostate Cancer Foundation and Department of Defense and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC), along with NRG Oncology. He was recently awarded a new R01 grant from the NCI, along with SKCC Director Karen Knudsen, PhD, to develop more effective therapeutic strategies for advanced prostate cancer.

“This is a well deserved honor for Dr. Kelly, who has been instrumental in bringing new therapeutic interventions to the forefront in the prostate cancer field. As one of the few cancer centers — and the only in Philadelphia — to have an NCI-designated Prostate Cancer Program of Excellence, Dr. Kelly has distinguished himself in the ability to serve the specialized needs of a large city that is challenged by a high incidence of and mortality from prostate cancer,” Knudsen said. “He now brings this leadership to the national level.”